TapewireFind a company

person · Reporting owner

Chambers Michael Andrew

Disclosed activity across 1 company

Tapewire entity
41120
SEC CIK
0001932527

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Sarepta Therapeutics, Inc.SRPT · Entity 4426DirectorJune 04, 2026June 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sarepta Therapeutics, Inc.

Report date June 04, 2026 · Filed June 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect27,535 Reported balance After 2026-06-04 transaction · row 1
1 source row

Row 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 27,535

F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Common StockSEC Table I · non-derivativeIndirectBy Revocable Trust476,492 Reported balance Holding disclosure · report date 2026-06-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 476,492

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 04, 2026 Filed Jun 6, 2026 00:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 16,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-260246 · ownership.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,535

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Read SEC document
December 18, 2025 Filed Dec 19, 2025 21:40 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantConvertible Senior Notes · Derivative Not disclosed Not disclosed Strike: $60.00 $20,000,000.00
Disclosure

SEC source: 0001193125-25-326980 · ownership.xml · derivative · entry 2

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: Not disclosed

Underlying: Common Stock · 333,333 shares

Expires not disclosed

F1 · date: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025.

F1 · price: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025.

F3 · derivative.exercise_date: The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

F3 · derivative.expiration_date: The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

F3 · derivative.underlying_shares: The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

Read SEC document
December 18, 2025 Filed Dec 19, 2025 21:40 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Disposition to issuerConvertible Senior Notes · Derivative Not disclosed Not disclosed Strike: $141.97 $20,000,000.00
Disclosure

SEC source: 0001193125-25-326980 · ownership.xml · derivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: Not disclosed

Underlying: Common Stock · 140,875 shares

Expires not disclosed

F1 · date: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025.

F1 · price: On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025.

F2 · derivative.exercise_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

F2 · derivative.expiration_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

F2 · derivative.underlying_shares: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Options (right to buy) · Derivative 4,792 $0.00 Strike: $99.69 $0.00
Disclosure

SEC source: 0000950170-25-037531 · ownership.xml · derivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,792

Underlying: Common Stock · 4,792 shares

Expires 2035-03-10

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 2,383 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-037531 · ownership.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,660

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 5,648 $134.66 $760,559.68
Disclosure

SEC source: 0000950170-24-098859 · ownership.xml · nonDerivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 284,034

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 18,284 $134.06 $2,451,153.04
Disclosure

SEC source: 0000950170-24-098859 · ownership.xml · nonDerivative · entry 2

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 278,386

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 13,106 $133.07 $1,744,015.42
Disclosure

SEC source: 0000950170-24-098859 · ownership.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 260,102

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 3,679 $0.00 Strike: $128.67 $0.00
Disclosure

SEC source: 0000950170-24-026613 · ownership.xml · derivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,679

Underlying: Common Stock · 3,679 shares

Expires 2034-03-01

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 1,846 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026613 · ownership.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,277

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 4,032 $109.89 $443,076.48
Disclosure

SEC source: 0001209191-23-045766 · doc4.xml · nonDerivative · entry 2

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 246,996

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $109.67 to $110, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 5,947 $109.19 $649,352.93
Disclosure

SEC source: 0001209191-23-045766 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 242,964

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 11, 2023 Filed Aug 14, 2023 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 23,686 $108.05 $2,559,272.30
Disclosure

SEC source: 0001209191-23-045498 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 237,017

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.70 to $108.48, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 10, 2023 Filed Aug 11, 2023 11:40 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 31,570 $106.26 $3,354,628.20
Disclosure

SEC source: 0001209191-23-045366 · doc4.xml · nonDerivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 213,331

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.01 to $106.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 10, 2023 Filed Aug 11, 2023 11:40 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 1,091 $105.90 $115,536.90
Disclosure

SEC source: 0001209191-23-045366 · doc4.xml · nonDerivative · entry 2

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 181,761

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105 to $106, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 10, 2023 Filed Aug 11, 2023 11:40 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 2,206 $104.67 $230,902.02
Disclosure

SEC source: 0001209191-23-045366 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Revocable Trust

Disclosed balance after: 180,670

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.99 to $104.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 3,257 $0.00 Strike: $155.99 $0.00
Disclosure

SEC source: 0001209191-23-017406 · doc4.xml · derivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,257

Underlying: Common Stock · 3,257 shares

Expires 2033-03-06

Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 1,523 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-017406 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,431

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024.

Read SEC document
September 14, 2022 Filed Sep 15, 2022 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 6,250 $105.16 $657,250.00
Disclosure

SEC source: 0001209191-22-050002 · doc4.xml · nonDerivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,178

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.085 to $105.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
September 14, 2022 Filed Sep 15, 2022 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 30,106 $104.67 $3,151,195.02
Disclosure

SEC source: 0001209191-22-050002 · doc4.xml · nonDerivative · entry 2

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,928

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $104.065 to $105.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
September 14, 2022 Filed Sep 15, 2022 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 20,744 $103.87 $2,154,679.28
Disclosure

SEC source: 0001209191-22-050002 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,822

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.06 to $104.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
September 13, 2022 Filed Sep 14, 2022 12:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantConvertible Senior Notes · Derivative Not disclosed $20,000,000.00 Strike: $141.97 $20,000,000.00
Disclosure

SEC source: 0001209191-22-049820 · doc4.xml · derivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Revocable Trust

Disclosed balance after: Not disclosed

Underlying: Common Stock · 140,879 shares

Expires not disclosed

F1 · date: On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions.

F1 · kind: On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions.

F2 · derivative.exercise_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

F2 · derivative.expiration_date: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

F2 · derivative.underlying_shares: The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

Read SEC document
August 19, 2022 Filed Aug 22, 2022 12:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 6,060 $108.80 $659,328.00
Disclosure

SEC source: 0001209191-22-046973 · doc4.xml · nonDerivative · entry 2

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,078

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.57 to $109.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
August 19, 2022 Filed Aug 22, 2022 12:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 40,110 $108.20 $4,339,902.00
Disclosure

SEC source: 0001209191-22-046973 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,018

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.56 to $108.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Read SEC document
June 02, 2022 Filed Jun 7, 2022 00:22 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 8,329 $0.00 Strike: $72.58 $0.00
Disclosure

SEC source: 0001209191-22-034739 · doc4.xml · derivative · entry 3

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,329

Underlying: Common Stock · 8,329 shares

Expires 2032-06-02

F2 · derivative.exercise_date: The option vests in three equal annual installments beginning June 2, 2023.

Read SEC document
June 02, 2022 Filed Jun 7, 2022 00:22 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 4,908 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-034739 · doc4.xml · nonDerivative · entry 1

Chambers Michael Andrew · CIK 0001932527 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,908

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning June 2, 2023.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.